Therapy News and Research

RSS

Bumetanide could treat children with severe autism or Asperger's syndrome

Although this therapy is not curative, it nevertheless reduced the autistic disorders' severity in three-quarters of the children. The researchers have filed a request for authorisation to perform a multi-centre European clinical trial in order to determine more precisely the population concerned by this therapy.

13 Dec 2012

AZD6765 briefly improves treatment-resistant patients' depression symptoms in minutes

A drug that works through the same brain mechanism as the fast-acting antidepressant ketamine briefly improved treatment-resistant patients' depression symptoms in minutes, with minimal untoward side effects, in a clinical trial conducted by the National Institutes of Health. The experimental agent, called AZD6765, acts through the brain's glutamate chemical messenger system.

13 Dec 2012

Dantrolene may help combat Duchenne muscular dystrophy in boys

Drugs are currently being tested that show promise in treating patients with Duchenne muscular dystrophy (DMD), an inherited disease that affects about one in 3,600 boys and results in muscle degeneration and, eventually, death.

13 Dec 2012

New listening device monitors effectiveness of kidney stone treatment

A new listening device, developed by scientists from the University of Southampton, is being used to monitor the effectiveness of the treatment of kidney stones - saving patients unnecessary repeat therapy and x-ray monitoring.

13 Dec 2012

TKI-resistant human leukemia stem cells are the source of genomic instability

An international team of scientists, led by researchers from Temple University School of Medicine, has found that a source of mounting genomic chaos, or instability, common to chronic myeloid leukemia (CML) may lie in a pool of leukemia stem cells that are immune to treatment with potent targeted anticancer drugs.

12 Dec 2012

Review describes current state of lung cancer care

A review in the December issue of the journal Archives of Pathology & Laboratory Medicine by Paul Bunn Jr, MD, University of Colorado Cancer Center investigator and past president of ASCO, IASLC and AACI describes the current state of lung cancer care.

12 Dec 2012

FDA grants Orphan Drug designation to Milo Biotechnology's AAV1-FS344 inhibitor

Milo Biotechnology today announced its AAV1-FS344 has been granted Orphan Drug designation from the FDA's Office of Orphan Products Development for treatment of Becker and Duchenne muscular dystrophy. AAV1-FS344 is a gene therapy-delivered myostatin inhibitor that increases muscle strength.

12 Dec 2012

Children with post-traumatic stress disorder (PTSD) may benefit from psychological therapies

Children suffering post-traumatic stress disorder (PTSD) as a result of traumatic events, including child abuse, may benefit from psychological therapies, according to a review published in The Cochrane Library.

12 Dec 2012

African–American rectal cancer patients wait the longest for treatment

African–American rectal cancer patients wait longer for treatment and are less likely to receive adjuvant chemotherapy than their non-African–American counterparts, results show.

12 Dec 2012

Inotuzumab ozogamicin selectively destroys malignant cells responsible for ALL in weekly dosing

A potent chemotherapy agent wrapped within a monoclonal antibody selectively destroys the malignant cells responsible for acute lymphocytic leukemia (ALL) in either weekly or monthly dosing, researchers report at the 54th ASH Annual Meeting and Exposition.

12 Dec 2012

Oncogene-induced senescence could play a key role in future cancer therapy

Cell aging, or cellular senescence, has an important role in the natural physiological response to tumor development. Activated oncogenes are able to induce senescence, and recent findings have suggested that oncogene-induced senescence (OIS) could play a key role in future cancer therapy.

12 Dec 2012

Acetazolamide plus autoCPAP may reduce insomnia and control sleep apnea at high altitudes

For individuals with obstructive sleep apnea traveling to higher altitudes (which may exacerbate symptoms), use of a combination therapy resulted in improvement in symptoms including reduced insomnia and better control of sleep apnea, according to a preliminary study published in the December 12 issue of JAMA.

12 Dec 2012

Activated astrocytes could play a harmful role in Alzheimer's disease

A research team composed of University of Kentucky researchers has published a paper which provides the first direct evidence that activated astrocytes could play a harmful role in Alzheimer's disease.

12 Dec 2012

Study identifies KNDy neurons as a likely control switch of hot flushes

Hot flushes affect millions of people, and not just women. Yet, it is still unclear what causes the episodes of temperature discomfort, often accompanied by profuse sweating.

12 Dec 2012

Blocking myeloid-derived suppressor cells after lymphopenia improves adoptive T-cell therapy

Researchers at the Moffitt Cancer Center have found that delayed tumor growth and enhanced survival of mice bearing melanoma were possible by blocking the reconstitution of myeloid-derived suppressor cells and Tregs (suppressors of anti-tumor activity) after total body irradiation had eliminated them. Blocking myeloid-derived suppressor cells and regulatory T-cell reconstitution improved adoptive T-cell therapy, an immunotherapy designed to suppress tumor activity.

12 Dec 2012

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Aeterna Zentaris Inc. today announced that final Phase 2 data demonstrated that the combination of perifosine, its oral AKT inhibitor, and sorafenib, was well tolerated by heavily pretreated patients with relapsed/refractory lymphomas.

12 Dec 2012

Astellas, FibroGen commence FG-4592/ASP1517 Phase 3 clinical program in CKD anemia

FibroGen, Inc., and Astellas Pharma Inc., announced today the initiation of the first clinical study in the Phase 3 clinical development program of FG-4592/ASP1517, an orally administered small molecule, for treatment of anemia associated with chronic kidney disease ("CKD") in patients not on dialysis and on dialysis, to support approval in the U.S. and Europe.

12 Dec 2012

Zucker Hillside Hospital celebrates opening of new $120 million inpatient pavilion

Zucker Hillside Hospital today celebrated the opening of a new 130,000-square-foot, $120 million inpatient pavilion. Constructed with the generous support of North Shore-LIJ Health System trustees Donald and Barbara Zucker and other donors, the 130,000-square-foot building will consolidate outdated living quarters dispersed across the psychiatric facility's campus, significantly improving the coordination of services and treatment along the continuum of care.

12 Dec 2012

Top-line results from Durata Therapeutics’ dalbavancin Phase 3 study on ABSSSI

Durata Therapeutics, Inc. today announced preliminary, top-line results for its DISCOVER 1 ("Dalbavancin for Infections of the Skin COmpared to Vancomycin at an Early Response") Phase 3 study of dalbavancin, which is under investigation for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible gram-positive bacteria, including MRSA (methicillin resistant Staphylococcus aureus).

11 Dec 2012

Dementia therapy: an interview with Assoc Prof. Olivier Piguet and Sharon Savage

Dementia is the umbrella term used to describe a number of neurodegenerative brain disorders that cause progressive changes in thinking abilities and behaviour. The kind of deficits experienced by individuals diagnosed with dementia depends on the location and severity of the pathology in the brain.

11 Dec 2012

Therapy News and Research

Bumetanide could treat children with severe autism or Asperger's syndrome

AZD6765 briefly improves treatment-resistant patients' depression symptoms in minutes

Dantrolene may help combat Duchenne muscular dystrophy in boys

New listening device monitors effectiveness of kidney stone treatment

TKI-resistant human leukemia stem cells are the source of genomic instability

Review describes current state of lung cancer care

FDA grants Orphan Drug designation to Milo Biotechnology's AAV1-FS344 inhibitor

Children with post-traumatic stress disorder (PTSD) may benefit from psychological therapies

African–American rectal cancer patients wait the longest for treatment

Inotuzumab ozogamicin selectively destroys malignant cells responsible for ALL in weekly dosing

Oncogene-induced senescence could play a key role in future cancer therapy

Acetazolamide plus autoCPAP may reduce insomnia and control sleep apnea at high altitudes

Activated astrocytes could play a harmful role in Alzheimer's disease

Study identifies KNDy neurons as a likely control switch of hot flushes

Blocking myeloid-derived suppressor cells after lymphopenia improves adoptive T-cell therapy

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Astellas, FibroGen commence FG-4592/ASP1517 Phase 3 clinical program in CKD anemia

Zucker Hillside Hospital celebrates opening of new $120 million inpatient pavilion

Top-line results from Durata Therapeutics’ dalbavancin Phase 3 study on ABSSSI

Dementia therapy: an interview with Assoc Prof. Olivier Piguet and Sharon Savage

Industry Focus eBook - Cell biology (5th edition) eBook

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News